211 related articles for article (PubMed ID: 15319024)
1. The Kutcher Generalized Social Anxiety Disorder Scale for Adolescents: assessment of its evaluative properties over the course of a 16-week pediatric psychopharmacotherapy trial.
Brooks SJ; Kutcher S
J Child Adolesc Psychopharmacol; 2004; 14(2):273-86. PubMed ID: 15319024
[TBL] [Abstract][Full Text] [Related]
2. The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial.
Brooks SJ; Krulewicz SP; Kutcher S
J Child Adolesc Psychopharmacol; 2003; 13(3):337-49. PubMed ID: 14642022
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
4. Psychometric properties of the Japanese version of the Social Phobia Inventory.
Nagata T; Nakajima T; Teo AR; Yamada H; Yoshimura C
Psychiatry Clin Neurosci; 2013 Apr; 67(3):160-6. PubMed ID: 23581867
[TBL] [Abstract][Full Text] [Related]
5. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
Baldwin D; Bobes J; Stein DJ; Scharwächter I; Faure M
Br J Psychiatry; 1999 Aug; 175():120-6. PubMed ID: 10627793
[TBL] [Abstract][Full Text] [Related]
6. The Liebowitz social anxiety scale for children and adolescents: an initial psychometric investigation.
Masia-Warner C; Storch EA; Pincus DB; Klein RG; Heimberg RG; Liebowitz MR
J Am Acad Child Adolesc Psychiatry; 2003 Sep; 42(9):1076-84. PubMed ID: 12960707
[TBL] [Abstract][Full Text] [Related]
7. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
Stein MB; Liebowitz MR; Lydiard RB; Pitts CD; Bushnell W; Gergel I
JAMA; 1998 Aug; 280(8):708-13. PubMed ID: 9728642
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the psychometric properties of two short forms of the social interaction anxiety scale and the social phobia scale.
Le Blanc AL; Bruce LC; Heimberg RG; Hope DA; Blanco C; Schneier FR; Liebowitz MR
Assessment; 2014 Jun; 21(3):312-23. PubMed ID: 24497625
[TBL] [Abstract][Full Text] [Related]
9. Buspirone in social phobia.
Schneier FR; Saoud JB; Campeas R; Fallon BA; Hollander E; Coplan J; Liebowitz MR
J Clin Psychopharmacol; 1993 Aug; 13(4):251-6. PubMed ID: 8376612
[TBL] [Abstract][Full Text] [Related]
10. Paroxetine in social phobia.
Mancini C; Ameringen MV
J Clin Psychiatry; 1996 Nov; 57(11):519-22. PubMed ID: 8968300
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine treatment of mood and anxiety disorders in children and adolescents.
Wagner KD
Psychopharmacol Bull; 2003; 37 Suppl 1():167-75. PubMed ID: 14566209
[TBL] [Abstract][Full Text] [Related]
13. [Validation of the Spanish version of the Liebowitz social anxiety scale, social anxiety and distress scale and Sheehan disability inventory for the evaluation of social phobia].
Bobes J; Badía X; Luque A; García M; González MP; Dal-Ré R
Med Clin (Barc); 1999 Apr; 112(14):530-8. PubMed ID: 10363239
[TBL] [Abstract][Full Text] [Related]
14. Psychometric properties of the dimensional anxiety scales for DSM-V in an unselected sample of German treatment seeking patients.
Beesdo-Baum K; Klotsche J; Knappe S; Craske MG; Lebeau RT; Hoyer J; Strobel A; Pieper L; Wittchen HU
Depress Anxiety; 2012 Dec; 29(12):1014-24. PubMed ID: 22933460
[TBL] [Abstract][Full Text] [Related]
15. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study.
Asakura S; Tajima O; Koyama T
Int J Neuropsychopharmacol; 2007 Apr; 10(2):263-74. PubMed ID: 16573847
[TBL] [Abstract][Full Text] [Related]
16. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.
Stein MB; Chartier MJ; Hazen AL; Kroft CD; Chale RA; Coté D; Walker JR
J Clin Psychopharmacol; 1996 Jun; 16(3):218-22. PubMed ID: 8784653
[TBL] [Abstract][Full Text] [Related]
17. Tridimensional personality questionnaire: assessment in patients with social phobia and a control group.
Kim SW; Hoover KM
Psychol Rep; 1996 Feb; 78(1):43-9. PubMed ID: 8839294
[TBL] [Abstract][Full Text] [Related]
18. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa.
Stein DJ; Berk M; Els C; Emsley RA; Gittelson L; Wilson D; Oakes R; Hunter B
S Afr Med J; 1999 Apr; 89(4):402-6. PubMed ID: 10341825
[TBL] [Abstract][Full Text] [Related]
19. Nefazodone in social phobia.
Van Ameringen M; Mancini C; Oakman JM
J Clin Psychiatry; 1999 Feb; 60(2):96-100. PubMed ID: 10084635
[TBL] [Abstract][Full Text] [Related]
20. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.
Stein MB; Sareen J; Hami S; Chao J
Am J Psychiatry; 2001 Oct; 158(10):1725-7. PubMed ID: 11579011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
